Schrödinger (SDGR) Q3 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2026 earnings summary
6 Nov, 2026Executive summary
Q3 revenue rose 19% YoY to $64.5M; ACV was $44.7M, up 17%, or 24% excluding contribution ACV. FY26 ACV and drug discovery revenue guidance increased.
Hosted adoption and a Structure Therapeutics milestone supported results; operating loss narrowed, while the net loss widened on equity-investment fair-value losses.
Financial highlights
Q3 total revenue was $64.5M versus $54.3M; gross profit was $38.3M versus $28.0M, and operating loss was $26.1M versus $45.9M.
Operating expenses were $64.4M, down 13% YoY; net loss was $37.7M versus $32.8M, with diluted loss per share of $0.50 versus $0.45.
Other expense included a $14.8M fair-value loss on equity investments; contribution revenue declined 60% to $2.1M as initial predictive-toxicology grant funding was completed.
9M revenue was $182.0M versus $168.6M; net loss narrowed to $91.8M from $135.8M.
Outlook and guidance
FY26 ACV guidance increased to $222M–$232M, implying 12%–17% growth over 2025; drug discovery revenue guidance rose to $75M–$85M from $65M–$75M.
FY26 operating expenses are expected below 2025; existing cash and securities are expected to cover operating and capital needs for at least 24 months.
Hosted-software transitions shift revenue recognition over contract terms and may contribute to near-term revenue declines.
2028 objectives include 10%–15% annual ACV growth, gross margin returning to the high 70s, $50M annual drug discovery revenue, and positive adjusted EBITDA by year-end.
Full commercial release of Bunsen was expected by year-end 2026; predictive toxicology capabilities were being made more broadly available during 2026.
Latest events from Schrödinger
- Bunsen aims to scale molecular discovery as ACV grows and hosted contracts expand.SDGR
UBS Global Healthcare Conference - AI-driven platform innovation and hosted solutions fuel growth, with profitability targeted by 2028.SDGR
Morgan Stanley 24th Annual Global Healthcare Conference - Q2 2026 saw 27% ACV growth, $58.9M revenue, and a return to profitability.SDGR
Q2 2026 - Shifting to R&D and partnerships, with robust revenue growth and key clinical data ahead.SDGR
Jefferies London Healthcare Conference 2025 - All proposals passed and strategic focus remains on AI-driven molecular discovery innovation.SDGR
AGM 2026 - 23% revenue growth to $255.9M, strong cash, and hosted transition target positive EBITDA by 2028.SDGR
Q4 2025 - Major Novartis deal and advancing clinical pipeline position the company for strong growth.SDGR
Jefferies London Healthcare Conference 2024 - Q2 revenue up 35% to $47.3M; net loss $54M; Gates grant and pipeline drive growth.SDGR
Q2 2024 - Novartis deal, strong software growth, and $398.4M cash offset lower drug discovery revenue.SDGR
Q3 2024